ArticleBiomedical optics express2014
In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.
Article in Biomedical optics express, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Medical hyperspectral imaging: an updated review of technology advancements and biomedical applications.Journal of biomedical optics · 2026Pooled it
- Hyperspectral imaging for tumor resection guidance in surgery: a systematic review of preclinical and clinical studies.Journal of biomedical optics · 2025Pooled it
- Systematic Meta-Analysis of Computer-Aided Detection of Breast Cancer Using Hyperspectral Imaging.Bioengineering (Basel, Switzerland) · 2024Review
- Endoscopic Hyperspectral Imaging System to Discriminate Tissue Characteristics in Tissue Phantom and Orthotopic Mouse Pancreatic Tumor Model.Bioengineering (Basel, Switzerland) · 2024Article
- Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.British journal of cancer · 2022Article
- Hyperspectral wide-field-of-view imaging to study dynamic microcirculatory changes during hypoxia.American journal of physiology. Heart and circulatory physiology · 2022Article
- Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer.Cancers · 2022Article
- Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity-From Bench to Bedside.Biomedicines · 2020Article
- Article
- The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.Cancers · 2020Article
- Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer.Mathematical medicine and biology : a journal of the IMA · 2019Article
- In-Vivo and Ex-Vivo Tissue Analysis through Hyperspectral Imaging Techniques: Revealing the Invisible Features of Cancer.Cancers · 2019Review
- Monitoring Breast Cancer Response to Treatment Using Stokes Shift Spectroscopy of Blood Plasma.Journal of fluorescence · 2019Article
- Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer.Neoplasia (New York, N.Y.) · 2019Article
- Hyperspectral imaging solutions for brain tissue metabolic and hemodynamic monitoring: past, current and future developments.Journal of optics (2010) · 2018Review
- Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.Nature communications · 2017Article
- Fluorescence hyperspectral imaging (fHSI) using a spectrally resolved detector array.Journal of biophotonics · 2017Article
- Monitoring the primo vascular system in lymphatic vessels by using window chambers.Biomedical optics express · 2016Article
- Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2.Bioconjugate chemistry · 2016Article
- Development of novel murine mammary imaging windows to examine wound healing effects on leukocyte trafficking in mammary tumors with intravital imaging.Intravital · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
HER2-amplified (HER2 + ) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2 + tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully, particularly in trastuzumab-resistant tumors. We used mouse models of trastuzumab sensitive and trastuzumab-resistant HER2 + breast cancers to measure dynamic changes in tumor microvessel density and hemoglobin oxygenation (sO2) in vivo using quantitative hyperspectral imaging at 2, 5, 9, and 14 days after antibody treatment. Further analysis quantified the distribution of microvessels into low and high oxygenation groups, and monitored changes in these distributions with trastuzumab treatment. Gold standard immunohistochemistry was performed to validate complementary markers of tumor cell and vascular response to treatment. Trastuzumab treatment in both responsive and resistant tumors resulted in decreased sO2 5 days after initial treatment when compared to IgG-treated controls (p<0.05). Importantly, responsive tumors showed significantly higher vessel density and significantly lower sO2 than all other groups at 5 days post-treatment (p<0.05). Distribution analysis of vessel sO2 showed a significant (p<0.05) shift of highly oxygenated vessels towards lower oxygenation over the time-course in both trastuzumab-treated responsive and resistant tumors. This study suggests that longitudinal hyperspectral imaging of microvessel sO2 and density could distinguish trastuzumab-responsive from trastuzumab-resistant tumors, a finding that could be exploited in the post-neoadjuvant setting to guide post-surgical treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.